Search Results 1071-1080 of 18043 for monoclonal antibody

  1. Mayo Clinic COVID-19 experts and focus areas Updated Dec. 3, 2021

    • Topics: COVID-19 therapeutics, including monoclonal antibody cocktail; inpatient treatment for COVID-19. • Dr. Badley video example: "Vaccines amid the ...

  2. Mayo Clinic Podcast - Dr. Gregory Poland - YouTube Audio Exp...

    antibody levels. So when exposed, they could develop disease ... Some of the mutations are making vaccines, plasma, monoclonal antibodies less effective.

  3. Publications - Pablo Moreno Franco, M.D. - Mayo Clinic

    ... Monoclonal Antibody Screening Score. Mayo Clin Proc Innov Qual Outcomes. 2023 Apr; 7 (2):109-121 Epub 2023 Jan 11. View PubMed; Shah SZ, Alvarez FG, Sanghavi ...

  4. A Study Of JNJ-68284528, A Therapy Directed Against B-Cell Maturation Antigen (BCMA) In Participants With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

    Monoclonal antibody treatment for multiple myeloma within 21 days;; Cytotoxic therapy within 14 days;; Proteasome inhibitor therapy within 14 days ...

  5. Tebentafusp Regimen Versus Investigator's Choice In Previously Treated Advanced Melanoma (TEBE-AM) - Mayo Clinic

    * previous severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb) * active autoimmune disease requiring immunosuppressive ...

  6. Oncology (Medical) - Clinical trials

    The purpose of this study is to assess the feasibility and develop procedures for detecting monoclonal proteins via finger pick blood spots and saliva. Data ...

  7. A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2) - Mayo Clinic

    antibody (TDB) antibody including non BCMA targeting TDB - Prior use of any monoclonal antibody (mAb), radioimmunoconjugate, or ADC as anti-cancer therapy ...

  8. Mayo Clinic Alzheimer's Disease Research Center Archives

    ... monoclonal antibody, lecanemab shows promise in removing amyloid plaques from the brain. Plaques are one of the defining features of Alzheimer's disease. Dr ...

  9. Study shows drug reduces risk of relapse with neuromyelitis optica - Mayo Clinic News Network

    ROCHESTER, Minn. — The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with ...

  10. Study To Evaluate Safety And Tolerability Of XmAb13676 In Patients With CD20-expressing Hematologic Malignancies - Mayo Clinic

    Known intolerance to CD20 monoclonal antibody therapy. History of primary central nervous system lymphoma or neoplastic central nervous system disease ...